Immuneering Corporation (Nasdaq: IMRX) said the FDA (U.S. drug regulator) approval of a new second-line treatment for metastatic pancreatic cancer is an important milestone for patients who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The company said attention now turns to first-line disease, where its oral MEK inhibitor atebimetinib is being tested with chemotherapy in the global randomized Phase 3 MAPKeeper 301 trial (NCT07562152). In an open-label, single-arm Phase 2a study, 55 first-line metastatic pancreatic cancer patients receiving atebimetinib 320 mg once daily plus modified gemcitabine/nab-paclitaxel recorded median overall survival of 17.3 months as of the April 24, 2026 data cutoff, with median follow-up of 11.6 months. At three months, 84% of evaluable patients maintained or gained weight. The only treatment-related adverse events occurring at Grade 3 or higher in at least 10% of patients were chemotherapy-related anemia, at 16%, and neutropenia, at 18%.